MYCN

A gene on chromosome 2p24.3 that encodes a DNA-binding transcription factor.

Molecular pathology
MYCN mutation causes Feingold syndrome; MYCN is amplified in various tumours, especially in neuroblastomas.

Mentioned in ?

References in periodicals archive ?

MYCN oncoprotein targets and their therapeutic potential.

Advances in the Surgical Treatment of Neuroblastoma

Intriguingly, MV4-11 cells do not express Mycn (Figure 5).

The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease

Lesne et al., "Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism," Oncotarget, vol.

Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors

Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.

MiR-34-a acts as a suppressor in neuroblastoma progression by targeting CD44

A key finding was that the researchers could block cancer cell self-renewal in the MYCN cells by blocking heme synthesis.

United States : Discovery points to drugs that would short-circuit deadly leukemia

Honna et al., "Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN," Bone Marrow Transplantation, vol.

High-Risk Neuroblastoma with Metastases to Bilateral Kidneys at Diagnosis

Cell line Site Stage Patient age Phase of therapy CHLA-15 Tumor 4 >1 DX CHLA-20 Tumor 4 1.5 PD-Ind CHLA-90 BM 4 8.5 PD-Auto-BMT LAN-5 BM Unknown 0.4 Unknown NUB-7 LN 4s/4 0.7 Unknown SH-SY5Y BM 4 4 PD-Ind BE(2)C BM 4 2.2 PD-Ind SK-N-BE(2) BM 4 2.2 PD-Ind Cell line MYCN amp p53 mutant CHLA-15 N WT CHLA-20 N WT CHLA-90 N Mut LAN-5 A WT NUB-7 A WT SH-SY5Y N WT BE(2)C A Mut SK-N-BE(2) A Mut BM = bone marrow; B = bone; L = liver; P = pulmonary; LN = lymph node; DX = at diagnosis; PD-Ind = progressive disease on induction chemotherapy; BMT = bone marrow transplantation; PD-Auto-BMT = relapsed after myeloablative chemo-radiotherapy followed by bone marrow transplantation; WT = wild type; Mut = mutant; N = nonamplified; A = amplified.

Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models

Vider et al., "MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas," The FASEB Journal, vol.

Cervical Cancer Cell Line Secretome Highlights the Roles of Transforming Growth Factor-Beta-Induced Protein ig-h3, Peroxiredoxin-2, and NRF2 on Cervical Carcinogenesis

Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea.

Cell cycle synchronization and BrdU incorporation as a tool to study the possible selective elimination of ErbBI gene in the micronuclei in A549 cells

The predicted targets of miR-145 were oncogenes myc myelocytomatosis viral-related oncogene (MYCN), FOS, and yamaguchi sarcoma oncogene (YES); cell-cycle promoters such as cyclins D2 and L1; and mitogen-activated protein kinase (MAPK) transduction proteins such as MAP3K3 and MAP4K4 [40].

The microRNAs as prognostic biomarkers for survival in esophageal cancer: a meta-analysis

Moreover, the oncogene MYCN, a member of the MYC family of basic helix-loop-helix transcription factors, has been described to bind the AURKA promoter either alone or in complex with the DNA methyl binding protein MeCP2 in the neuroblastoma derived cell line Kelly [14].

A new aurora in anaplastic thyroid cancer therapy

Clinically relevant pediatric factors that influence survival in children include stage, age, histology, tumor grade, MYCN oncogene status, chromosome 11q status, and DNA ploidy.

Adult versus pediatric neuroblastoma: the M.D. Anderson Cancer Center experience